Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides
Authors:
- Céline PellatonCPCéline Pellaton
- Yannick PerrinYPYannick Perrin
- Caroline BoudousquiéCBCaroline Boudousquié
- Nathalie BarbierNBNathalie Barbier
- Jacqueline WassenbergJWJacqueline Wassenberg
- Giampietro CorradinGCGiampietro Corradin
- Anne‐Christine ThierryATAnne‐Christine Thierry
- Régine AudranRARégine Audran
- Christophe ReymondCRChristophe Reymond
- François SpertiniFSFrançois Spertini
Open Access
- 1 January 2013
- journal article
- Published by Wiley in Clinical and Translational Allergy
- Vol. 3 (1) , 17
Abstract
Background: Synthetic contiguous overlapping peptides (COPs) may represent an alternative to allergen extracts or recombinant allergens for allergen specific immunotherapy. In combination, COPs encompass the entire allergen sequence, providing all potential T cell epitopes, while preventing IgE conformational epitopes of the native allergen.Methods: Individual COPs were derived from the sequence of Bet v 1, the major allergen of birch pollen, and its known crystal structure, and designed to avoid IgE binding. Three sets of COPs were tested in vitro in competition ELISA and basophil degranulation assays. Their in vivo reactivity was determined by intraperitoneal challenge in rBet v 1 sensitized mice as well as by skin prick tests in volunteers with allergic rhinoconjunctivitis to birch pollen.Results: The combination, named AllerT, of three COPs selected for undetectable IgE binding in competition assays and for the absence of basophil activation in vitro was unable to induce anaphylaxis in sensitized mice in contrast to rBet v 1. In addition no positive reactivity to AllerT was observed in skin prick tests in human volunteers allergic to birch pollen. In contrast, a second set of COPs, AllerT4‐T5 displayed some residual IgE binding in competition ELISA and a weak subliminal reactivity to skin prick testing.Conclusions: The hypoallergenicity of contiguous overlapping peptides was confirmed by low, if any, IgE binding activity in vitro, by the absence of basophil activation and the absence of in vivo induction of allergic reactions in mouse and human.Trial registration: ClinicalTrials.gov NCT01719133Keywords
Funding Information
- Crystal Technology and Industries
This publication has 55 references indexed in Scilit:
- Molecular diagnosis of fruit and vegetable allergyCurrent Opinion in Allergy and Clinical Immunology, 2011
- Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollenAllergy and Asthma Proceedings, 2011
- Mouse and human neutrophils induce anaphylaxisJournal of Clinical Investigation, 2011
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- The impact of pollen‐related food allergens on pollen allergyAllergy, 2006
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1–related food allergensJournal of Allergy and Clinical Immunology, 2005
- Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapyEuropean Journal of Immunology, 2002
- Three-Dimensional Structure and Epitopes of Bet v 1International Archives of Allergy and Immunology, 1997
- Structural consequences of sequence patterns in the fingerprint region of the nucleotide binding foldJournal of Molecular Biology, 1992